STOCK MARKET BSE NSE

COVID-19 vaccination: Govt to share probe info on deaths after jab to build trust

Ever since the rollout of the vaccines a week ago, five deaths have been reported, but their AEFI reports tied them to comorbidities and not the vaccine.

Published: 23rd January 2021 09:00 AM  |   Last Updated: 23rd January 2021 09:00 AM   |  A+A-

A health worker administering Covid-19 vaccine to a woman in Tirupati.

A health worker administering Covid-19 vaccine to a woman in Tirupati. (Photo | Madhav K, EPS)

Express News Service

NEW DELHI:  The Centre has decided to make public the findings of  probes into all serious adverse events following immunisation (AEFI)  for Covid-19 from next week to build confidence around the vaccines, as they have received less than enthusiastic response from beneficiaries so far.

ALSO READ | Over 1 lakh Telangana health workers given Covid-19 vaccine in five days

Ever since the rollout of the vaccines a week ago, five deaths have been reported, but their AEFI reports tied them to comorbidities and not the vaccine. But the fatalities seem to have exacerbated the vaccine hesitancy among healthcare workers. “It is an attempt to improve communication with the targeted groups and build trust,” said a health ministry official. 

A member in the ICMR’s ethics panel explained that as the rollout advances, particularly in those who are in their 70s and 80s, there could be more such deaths. “People need to understand that because there is a rigorous AEFI tracking mechanism, it will capture all of these deaths,” he said.

ALSO READ | Nine adverse events in Karnataka since vaccine launch

“There is a background death rate in all age groups — a U-shaped curve, high between 0 to 1 years, then falls, the lowest in the 20 to 40 age group, then rises after 40, and sharply rises in older age groups. The AEFI plan will capture all these deaths among vaccine recipients,” he added.

PM dispels fears
Prime Minister Narendra Modi on Friday said he went by the decision of scientists on the vaccine rollout, adding it was not a political call, and obliquely referred to the controversy around the nod to Bharat Biotech’s Covaxin 



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp